TY  - JOUR
A1  - Hartmann, Sylvia
A1  - Plütschow, Annette
A1  - Mottok, Anja
A1  - Bernd, Heinz‐Wolfram
A1  - Feller, Alfred C.
A1  - Ott, German
A1  - Cogliatti, Sergio
A1  - Fend, Falko
A1  - Quintanilla‐Martinez, Leticia
A1  - Stein, Harald
A1  - Klapper, Wolfram
A1  - Möller, Peter
A1  - Rosenwald, Andreas
A1  - Engert, Andreas
A1  - Hansmann, Martin‐Leo
A1  - Eichenauer, Dennis A.
T1  - The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
JF  - American Journal of Hematology
N2  - Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) can present with different histopathological growth patterns. The impact of these histopathological growth patterns on relapse characteristics is unknown. We therefore analyzed paired biopsies obtained at initial diagnosis and relapse from 33 NLPHL patients who had received first‐line treatment within German Hodgkin Study Group (GHSG) trial protocols, and from a second cohort of 41 relapsed NLPHL patients who had been treated outside GHSG studies. Among the 33 GHSG patients, 21 patients presented with a typical growth pattern at initial diagnosis, whereas 12 patients had a variant histology. The histopathological growth patterns at initial diagnosis and at relapse were consistent in 67% of cases. A variant histology at initial diagnosis was associated with a shorter median time to lymphoma recurrence (2.8 vs 5.2 years; P = .0219). A similar tendency towards a shorter median time to lymphoma recurrence was observed for patients presenting with a variant histology at relapse, irrespective of the growth pattern at initial diagnosis. Results obtained from the 41 NLPHL patients who had been treated outside GHSG studies were comparable (median time to lymphoma recurrence for variant histology vs typical growth pattern at initial diagnosis: 1.5 vs 7.0 years). In conclusion, the histopathological growth pattern remains consistent at relapse in the majority of NLPHL cases, and has major impact on the time of relapse.
KW  - Hodgkin lymphoma
KW  - relapse
KW  - growth patterns
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-212594
VL  - 94
IS  - 11
SP  - 1208
EP  - 1213
ER  - 
TY  - JOUR
A1  - Gerhard-Hartmann, Elena
A1  - Goergen, Helen
A1  - Bröckelmann, Paul J.
A1  - Mottok, Anja
A1  - Steinmüller, Tabea
A1  - Grund, Johanna
A1  - Zamò, Alberto
A1  - Ben-Neriah, Susana
A1  - Sasse, Stephanie
A1  - Borchmann, Sven
A1  - Fuchs, Michael
A1  - Borchmann, Peter
A1  - Reinke, Sarah
A1  - Engert, Andreas
A1  - Veldman, Johanna
A1  - Diepstra, Arjan
A1  - Klapper, Wolfram
A1  - Rosenwald, Andreas
T1  - 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
JF  - British Journal of Haematology
N2  - High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced-stage or r/r cHL. All but two cases (97%) showed PD-L1 expression by the tumour cells in variable amounts. While MHC-I was rarely expressed in >50% of HRSC, MHC-II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD-L1 and MHC-I/II expression on early response to the highly effective anti-PD-1-based NIVAHL first-line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti-PD-1 first-line cHL treatment.
KW  - fluorescence in situ hybridisation
KW  - major histocompatibility complex
KW  - immune checkpoint blockade
KW  - classical Hodgkin lymphoma
KW  - CD274
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-258358
VL  - 196
IS  - 1
ER  -